-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

3339 The Influence of High-Efficiency Particulate Air Filtration on Mortality Among Multiple Myeloma Patients Receiving Autologous Stem Cell Transplantation: A Nationwide Population-Based Study

Program: Oral and Poster Abstracts
Session: 731. Clinical Autologous Transplantation: Results: Poster III
Hematology Disease Topics & Pathways:
multiple myeloma, Adult, Diseases, Plasma Cell Disorders, Lymphoid Malignancies, Study Population, Clinically relevant
Monday, December 7, 2020, 7:00 AM-3:30 PM

Chun-Kuang Tsai, MD1*, Chiu-Mei Yeh, MS1,2*, Ying-Chung Hong, MD3*, Po-Min Chen, MD. PhD.1*, Jin-Hwang Liu, MD. PhD.4,5*, Jyh-Pyng Gau, MD1* and Chia-Jen Liu, MD1,6

1Division of Hematology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan
2Institute of Public Health, National Yang-Ming University, Taipei, Taiwan
3Division of Hematology and Oncology, Kaohsiung Veterans General Hospital, Kaohsiung, TWN
4Division of Hematology and Oncology, Cheng Hsin General Hospital, Taipei, Taiwan, Taipei, Taiwan
5Chong Hin Loon Cancer and Biotherapy Research Center and Institute of Biopharmaceutical Sciences, National Yang-Ming University, Taipei, Taiwan
6Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA


Multiple myeloma (MM) is a common hematologic neoplasm in Taiwan. Autologous stem cell transplantation (ASCT) is encouraged for transplant-eligible MM patients. A part of MM patients received ASCT in an isolation room with high-efficiency particulate air (HEPA) filtration. The effectiveness of the HEPA filtration on reducing treatment-related mortality or infection among ASCT patients is still controversial.


We enrolled patients with newly diagnosed MM in Taiwan between January 1, 2000 and December 31, 2017. The patients who were under 20 years, without ASCT, or receiving non-melphalan conditioning regimens were excluded. The primary endpoint of the study was treatment-related mortality, which was defined as death within 100 days after receiving ASCT. Only the first ASCT was analyzed. A Cox proportional hazards model was used to adjust for potential confounding factors in the multivariate analysis. The factors with p < 0.1 in the univariate analysis were included in the multivariate analysis.


A total of 961 MM patients received ASCT during the 18-year study period. The median age of the patients was 57 years (range 28–76 years) and 54.9% were men. Of them, 480 patients (49.9%) received ASCT in an isolation room with HEPA filtration (HEPA group). The median overall survival from ASCT was 7.52 years (95% CI 6.00–8.73) for the HEPA group while it was 5.88 years (95% CI 4.99–8.46) for the remaining patients (non-HEPA group). The 100-day mortality rate was 1.5% and 1.0% for the HEPA and non-HEPA groups, respectively. The crude hazard ratio (HR) for the 100-day mortality HEPA group was 1.39 (95% confidence interval [CI] 0.44–4.37, p = 0.576) compared to the non-HEPA group. In the univariate analysis, only coronary artery disease (HR 5.80) and end-stage renal disease (HR 5.46) were associated with 100-day mortality. After adjusting for the variables found in univariate analysis, the 100-day mortality still had no difference between the HEPA and non-HEPA groups (adjusted HR 1.65, 95% CI 0.52–5.23, p = 0.399).


Although about 50% of MM patients in Taiwan received ASCT in an isolation room with HEPA filtration, we found that it didn’t affect 100-day mortality. This study may help clinicians allocate the limited resource of the HSCT facilities. Further validation of our findings in other cohorts is warranted.

Disclosures: No relevant conflicts of interest to declare.

*signifies non-member of ASH